Table 3. Univariate anaylsis of factors associated with disease-free and overall survival for HER2-positive primary breast cancer patients in the first set.
|
Disease-free survival |
Overall survival |
|||||
|---|---|---|---|---|---|---|
| Variables | HR | 95% CI | P-value | HR | 95% CI | P-value |
|
EGFR overexpression (3+) | ||||||
| Negative | — | — | ||||
| Positive | 3.593 | 1.774–7.278 | <0.001 | 1.928 | 0.870–4.273 | 0.106 |
|
EGFR overexpression (2+ or more) | ||||||
| Negative | — | — | ||||
| Positive | 2.121 | 1.100–4.089 | 0.025 | 1.403 | 0.703–2.799 | 0.337 |
|
High EGFR copy number | ||||||
| Negative | — | — | ||||
| Positive | 0.68 | 0.209–2.208 | 0.521 | 0.798 | 0.244–2.594 | 0.704 |
|
Age (years) | ||||||
| <50 | — | — | ||||
| ⩾50 | 1.284 | 0.690–2.388 | 0.431 | 1.256 | 0.662–2.385 | 0.485 |
|
pT stage | ||||||
| T1 | — | — | ||||
| T2–T4 | 2.214 | 1.105–4.436 | 0.025 | 1.387 | 0.716–2.684 | 0.332 |
|
pN stage | ||||||
| N0 | — | — | ||||
| N1–N3 | 5.832 | 2.579–13.191 | <0.001 | 3.654 | 1.727–7.732 | 0.001 |
|
Histologic grade | ||||||
| I and II | — | — | ||||
| III | 1.492 | 0.707–3.148 | 0.294 | 1.264 | 0.613–2.607 | 0.526 |
|
Lymphovascular invasion | ||||||
| Negative | — | — | ||||
| Positive | 1.756 | 0.944–3.269 | 0.076 | 1.668 | 0.903–3.081 | 0.102 |
|
Hormone receptor status | ||||||
| Negative | — | — | ||||
| Positive | 0.672 | 0.342–1.318 | 0.247 | 0.751 | 0.379–1.489 | 0.413 |
|
p53 expression | ||||||
| Negative | — | — | ||||
| Positive | 0.829 | 0.440–1.562 | 0.562 | 0.962 | 0.535–1.930 | 1.016 |
|
Adjuvant trastuzumab | ||||||
| Not received | — | — | ||||
| Received | 0.804 | 0.212–3.048 | 0.748 | 1.289 | 0.318–5.225 | 0.723 |
|
Adjuvant chemotherapy | ||||||
| Not received | — | — | ||||
| Received | 0.582 | 0.257–1.317 | 0.194 | 0.561 | 0.246–1.279 | 0.169 |
Abbreviations: CI=confidence interval; EGFR=epidermal growth factor receptor; HR=hazard ratio.